Idiopathic Pulmonary Fibrosis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Idiopathic Pulmonary Fibrosis Treatment Market was valued at USD 3 billion in 2023 and is projected to expand at a CAGR of 6.9% from 2024 to 2032. This growth is driven by the rising incidence of idiopathic pulmonary fibrosis (IPF), linked to aging populations and environmental factors.

As the global population ages, the prevalence of IPF challenges healthcare systems worldwide. Data from the National Institutes of Health shows IPF is more common in men, with North American rates ranging from 2.40 to 2.98 cases per 10,000 individuals. This prevalence has spurred innovations in treatment, including targeted therapies and immunotherapies, broadening patient care options and fueling market expansion.

Advances in diagnostic technologies have been crucial for the timely detection and management of IPF. Advanced imaging systems and non-invasive tools enable healthcare professionals to identify IPF earlier. Early detection allows for timely interventions, enhancing patient outcomes and driving market growth.

The overall idiopathic pulmonary fibrosis treatment industry is classified based on treatment type, route of administration, age group, end-use, and region.

In 2023, the drug class segment led the market with a valuation of USD 1.8 billion. This growth is due to increased awareness, timely diagnoses, and improved drug efficacy. NIH data indicates that around 100,000 individuals in the U.S. are diagnosed with IPF annually. The drug class segment includes antifibrotic drugs, anti-inflammatory drugs, corticosteroids, immunosuppressants, and others. Antifibrotic drugs like pirfenidone and nintedanib dominate due to their ability to slow disease progression. Corticosteroids have declined in preference due to limited effectiveness, while immunosuppressants such as azathioprine and mycophenolate mofetil are used in select cases, often alongside corticosteroids.

In 2023, the adult segment led the market with a valuation of USD 2 billion due to the disease's higher prevalence in those aged 50 and above. With age being a significant factor in IPF incidence, older adults are the primary focus for treatment. This segment's growth is further bolstered by the global aging trend and advancements in awareness and diagnostics. NIH data notes that while 100,000 people in the U.S. are affected by IPF, a significant majority are adults over 65.

North America idiopathic pulmonary fibrosis treatment market is set to reach USD 2.5 billion by 2032, with a projected CAGR of 6.8% over the forecast period. The U.S. commands a dominant position in this market. Factors contributing to the rising IPF prevalence in the U.S. include an aging demographic, genetic factors, and environmental influences. The region's advanced medical infrastructure and strong R&D capabilities significantly shape the IPF treatment landscape. Moreover, robust collaborations among pharmaceutical firms, research entities, and healthcare professionals drive innovation and ensure effective treatment availability. As awareness grows and the disease's incidence rises among older demographics, the market is poised for continued expansion.

Product Code: 11108

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence and prevalence of IPF
  - 3.2.1.2 Advancements in diagnostic techniques
  - 3.2.1.3 Enhanced patient awareness of IPF
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment cost
  - 3.2.2.2 Limited efficacy and side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Drug class
- 5.2.1 Antifibrotic agents
- 5.2.2 Anti-inflammatory
- 5.2.3 Corticosteroids
- 5.2.4 Immunosuppressants
- 5.2.5 Other drug classes
5.3 Therapy
- 5.3.1 Oxygen therapy
- 5.3.2 Pulmonary rehabilitation
5.4 Lung transplantation

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Adult
7.3 Geriatric

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals and clinics
8.3 Ambulatory surgical centers (ASCs)
8.4 Homecare settings
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Service Provider
- 10.1.1 Bumrungrad International Hospital
- 10.1.2 Cedars-Sinai
- 10.1.3 Cleveland Clinic
- 10.1.4 Dr. Sulaiman Al-Habib Medical Group
- 10.1.5 Nicklaus Children's Hospital
10.2 Medication Manufacturer
- 10.2.1 Boehringer Ingelheim International GmbH
- 10.2.2 Bristol-Myers Squibb Company
- 10.2.3 Cipla Inc.
- 10.2.4 F. Hoffmann-La Roche Ltd
- 10.2.5 FibroGen, Inc.
- 10.2.6 Galapagos NV
- 10.2.7 Liminal BioSciences Inc.
- 10.2.8 MediciNova, Inc.
- 10.2.9 Novartis AG
- 10.2.10 United Therapeutics